AI could replace biopsies for bladder cancer testing
NCT ID NCT07454941
First seen Mar 27, 2026 · Last updated Jun 23, 2026 · Updated 19 times
Summary
This study enrolls 4,000 people with urothelial carcinoma to test whether artificial intelligence can predict HER2 expression using MRI scans and pathology images. The goal is to create a model that accurately assesses HER2 status without needing invasive biopsies, helping doctors decide on targeted therapy faster. Researchers will also use AI to diagnose tumor type, grade, and invasiveness from pre-treatment images.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences Beijing
Beijing, Chaoyang District, 100021, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Artificial intelligence model
What this could lead to
If successful, this AI model could quickly and accurately predict HER2 status from MRI scans, helping doctors choose the right targeted therapy without needing a biopsy.
What could go wrong
This is an early-stage model validation study, not a treatment trial. The AI may not be accurate enough in real-world settings, and results may not apply to all patients or hospitals.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.